Caracemide

Research use only, not for human use.

Caracemide inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide can be used in anticancer studies.

Caracemide inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide can be used in anticancer studies.(In Vitro):Caracemide produces severe central nervous system (CNS) toxicity because of the toxic metabolite, methylisocyanate (MIC). Caracemide inactivates R1 by covalent modification at the substrate-binding site.(In Vivo):After administration of Caracemide (6.6 mg/kg;i.p.), the mercapturic acid derivative AMCC was identified in rats urine.

Caracemide inactivates R1 by covalent modification at the substrate-binding site and has a toxic metabolite, methylisocyanate (MIC), in vivo.

The mercapturic acid derivative AMCC was identified in urine rats following administration to rats of a single i.p. dose (6.6 mg/kg) of caracemide (NSC-253272). .

NSC-253272

Others

Other Targets

Anti-infection| Bacterial

——

——

81424-67-1

189.171

C6H11N3O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (528.63 mM)

CNC(=O)ON(C(C)=O)C(=O)NC

——

(-20℃)

With Ice Pack

≥ 2 years